GeneDx stock (NASDAQ: WGS) plunged 14% on Monday after the genomics testing company released preliminary full-year 2025 results that met expectations. But the company unveiled 2026 guidance that ...

GeneDx reported full-year 2025 revenue of approximately $427M, inline with consensus of $427M, representing a 41% year-over-year increase and within its previously raised guidance range of $425 ...

Genedx Holding Corp. launched Genomedx Prenatal, its whole genome sequencing test, to provide more definitive diagnoses of the causes of fetal abnormalities identified by ultrasound. By combining the ...

Labcorp added to its suite of tests designed to detect cancer recurrence much earlier than traditional imaging.

GeneDx Holdings ( (WGS) ) has issued an announcement.

GeneDx announced GenomeDx Prenatal™, a whole genome sequencing test that delivers fast, comprehensive insights when fetal ...

GeneDx Holdings Corp. , a leader in delivering improved health outcomes through genomic insights, today reported preliminary financial results for the fourth quarter and full year of 2025. "In 2025, ...

GeneDx , a leader in delivering improved health outcomes through genomic insights, today announced GenomeDx Prenataltm, whole genome sequencing (WGS) designed to deliver clear, reliable answers during ...

Investing.com -- GeneDx Holdings Corp (NASDAQ:WGS) stock fell 14% Monday after the genomic testing company’s 2026 guidance failed to impress investors despite reporting solid preliminary results for ...

The region’s hub of diagnostics and testing firms saw a slight increase in employment for the first time in four years, ...

A new study reveals that genetic technology can identify male infertility causes, enhancing IVF decisions and reducing ...

Industry leaders say demand for these higher-value tests aimed at early disease detection, personalised treatment and long-term health management has been expanding far faster than routine pathology ...